1 results match your criteria: "University of Miami. Electronic address: kazandjiandg@mail.nih.gov.[Affiliation]"
Current and prospective antibody-based therapies in multiple myeloma.
Semin Oncol
February 2022
Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami. Electronic address:
Multiple Myeloma (MM) is a hematologic malignancy involving clonal plasma cell proliferation. Unfortunately, MM remains an incurable disease. Over the past five years, the incorporation of novel monoclonal antibodies has synergized with standard of care to improve patient outcomes in both newly diagnosed MM as well as relapsed and refractory MM.
View Article and Find Full Text PDF